Megadolichobasilar anomaly with thrombosis in a family with Fabry's diseaseand a novel mutation in the α-galactosidase A gene

被引:38
作者
Garzuly, F
Maródi, L
Erdös, M
Grubits, J
Varga, Z
Gelpi, E
Rohonyi, B
Mázló, M
Molnár, A
Budka, H
机构
[1] Med Univ Vienna, Inst Neurol, A-1097 Vienna, Austria
[2] Markusovszky Hosp, Dept Neurol, Szombathely, Hungary
[3] Univ Debrecen, Med & Hlth Sci Ctr, Dept Infectol & Pediat Immunol, Debrecen, Hungary
[4] Erzsebet Hosp, Dept Neurol, Sopron, Hungary
[5] Erzsebet Hosp, Dept Pathol, Sopron, Hungary
[6] Univ Pecs, Fac Med, Cent Electron Microscopy Lab, Pecs, Hungary
[7] Dr Batthyany Strattmann Laszlo Hosp, Dermatol Hlth Ctr, Kormend, Hungary
基金
匈牙利科学研究基金会;
关键词
megadolichobasilar anomaly; basilar thrombosis; Fabry's disease; angiokeratoma corporis diffusum; GLA mutation;
D O I
10.1093/brain/awh546
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Fabry's disease is an X-linked lysosomal storage disorder. alpha-Galactosidase deficiency leads to accumulation of globotriaosylceramide mainly in endothelial and smooth muscle cells. Cerebrovascular symptoms with predominant affection of the vertebrobasilar circulation are one of the major sources of morbidity in Fabry's disease. We present a Hungarian family with Fabry's disease caused by a new mutation in the alpha-galactosidase A gene (GLA), and describe a variant expression of the disease. Megadolichobasilar anomaly was diagnosed in two male patients in the family who died of thrombosis. In another female patient who had suffered from disturbance of the vertebrobasilar circulation, a strongly dilated basilar artery without thrombosis was found at autopsy. Another three family members had basilar strokes and large and elongated basilar arteries on MRI. Genetic analysis disclosed a c.47T -> C missense mutation resulting in L16P in the amino acid sequence of the alpha-galactosidase protein. This report suggests that megadolichobasilar anomaly is potentially life-threatening, and that L16P is a disease-causing mutation in patients with Fabry's disease. Early enzyme replacement therapy may prevent the development of these irreversible cerebrovascular complications.
引用
收藏
页码:2078 / 2083
页数:6
相关论文
共 30 条
[1]  
Anderson W., 1898, BRIT J DERMATOL, V10, P113, DOI DOI 10.1111/J.1365-2133.1898.TB16317.X
[2]   NEUROLOGICAL MANIFESTATIONS OF FABRY DISEASE IN FEMALE CARRIERS [J].
BIRD, TD ;
LAGUNOFF, D .
ANNALS OF NEUROLOGY, 1978, 4 (06) :537-540
[3]   THE MEGADOLICHOBASILAR ANOMALY [J].
BOERI, R ;
PASSERINI, A .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1964, 1 (05) :475-484
[4]   ENZYMATIC DEFECT IN FABRYS DISEASE - CERAMIDETRIHEXOSIDASE DEFICIENCY [J].
BRADY, RO ;
GAL, AE ;
BRADLEY, RM ;
MARTENSS.E ;
WARSHAW, AL ;
LASTER, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (21) :1163-&
[5]  
Brittig F, 1986, Morphol Igazsagugyi Orv Sz, V26, P15
[6]  
CROISILE B, 1988, NEUROCHIRURGIE, V34, P342
[7]   Quantitative analysis of cerebral vasculopathy in patients with Fabry disease [J].
Crutchfield, KE ;
Patronas, NJ ;
Dambrosia, JM ;
Frei, KP ;
Banerjee, TK ;
Barton, NW ;
Schiffmann, R .
NEUROLOGY, 1998, 50 (06) :1746-1749
[8]  
D'Andrea F, 1992, Acta Neurol (Napoli), V14, P611
[9]  
DeGraba T, 2000, ANN NEUROL, V47, P229, DOI 10.1002/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO
[10]  
2-T